Inhaled Nitric Oxide (iNO) Delivery System Market Size, Trends, Share, and Growth Forecast, 2026 - 2033

The global inhaled nitric oxide (iNO) delivery system market size is likely to be valued at US$ 379.0 million in 2026 and is projected to reach US$762.0 million by 2033, growing at a CAGR of 10.5% during the forecast period 2026−2033.  This robust expansion is driven by a rising global incidence of neonatal respiratory distress syndrome (nRDS) and pulmonary arterial hypertension (PAH), coupled with widening regulatory approvals across emerging economies.

Technological evolution in portable and non-electric iNO delivery platforms is unlocking new care settings beyond the ICU, while growing awareness among neonatologists and pulmonologists is accelerating clinical adoption. The expanding neonatal care infrastructure in the Asia Pacific and Latin America, combined with favorable reimbursement policy revisions in the U.S. and European Union.

• Dominant Region: North America is expected to command about a 45% market share in 2026, supported by a strong healthcare infrastructure and sustained government investment in medical services.
• Fastest-growing Region: The Asia Pacific market is the fastest-growing during the forecast period, due to increasing healthcare expenditure, rising awareness about respiratory care, and expanding medical infrastructure.
• Leading & Fastest-growing Application: Neonatal respiratory treatment currently dominates the segment, commanding approximately 55% of total market revenue. Acute respiratory distress syndrome is likely to be the fastest-growing segment during the 2026-2033 forecast period.
• Leading & Fastest-growing End-user: Hospitals represent the dominant application segment, capturing approximately 70% of market revenue share in 2026. Specialty clinics are expected to be the fastest-growing segment over the forecast period.

Rising Prevalence of Neonatal Respiratory Disorders

Neonatal respiratory distress syndrome (nRDS) and persistent pulmonary hypertension of the newborn (PPHN) are driving a substantial increase in neonatal intensive care unit (NICU) admissions worldwide. Premature infants are particularly vulnerable to these conditions, often requiring specialized respiratory support to stabilize their lung function and oxygenation. Inhaled nitric oxide (iNO) therapy is emerging as a cornerstone treatment for PPHN, offering targeted vasodilation in the pulmonary arteries and improving oxygen delivery. Hospitals and neonatal care centers are continually expanding their capacity to provide advanced respiratory therapies, reflecting both the growing awareness of early intervention benefits and the increasing emphasis on improving survival outcomes for critically ill newborns.

The prevalence of preterm births and related respiratory complications is steadily contributing to a larger treatable patient population, especially in regions where neonatal survival rates are improving due to better healthcare infrastructure and access to medical technology. According to the World Health Organization (WHO), an estimated 13.4 million babies were born preterm in 2020 (before 37 completed weeks of gestation). As more infants survive early life complications, the demand for therapies such as iNO will continue rising, prompting investment in both clinical resources and supportive technologies. This expanding patient base is influencing market dynamics, encouraging innovation, and ensuring that therapeutic interventions keep pace with evolving clinical needs.

Technological Advancements in Portable Delivery Systems

Hospital-grade inhaled nitric oxide (iNO) delivery systems are evolving to meet the needs of modern neonatal and critical care environments. Portable, lightweight, and battery-operated devices are enabling therapy administration beyond traditional intensive care units, extending treatment to transport scenarios and community hospitals. These systems are integrating advances in sensor miniaturization, precise flow control algorithms, and continuous monitoring of nitric oxide (NO) and nitrogen dioxide (NO2) levels, which are enhancing safety and reliability. By reducing the complexity and space requirements of traditional devices, these next-generation platforms are improving workflow efficiency for healthcare providers and making therapy more accessible in diverse care settings.

The innovation momentum within the medical device industry is creating an environment that supports faster adoption of advanced iNO systems. Research and development (R&D) efforts are focusing on improving portability, usability, and integration with existing hospital infrastructure, ensuring that neonatal and critical care teams can deliver therapy safely and effectively. Emerging markets are expected to benefit from this trend as health systems adopt modern devices to expand access to life-saving treatments. The convergence of technology miniaturization, improved monitoring capabilities, and cost-efficient designs will be continuously reshaping the iNO delivery landscape, positioning the segment for sustained growth and wider clinical penetration.

Stringent Regulatory Frameworks for Device Approval

Inhaled nitric oxide delivery systems are considered high-risk medical devices and are subject to rigorous regulatory oversight. Agencies such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and Pharmaceuticals and Medical Devices Agency (PMDA) in Japan require extensive clinical validation before approving. Manufacturers are conducting comprehensive safety and efficacy studies to meet stringent standards, which ensure that devices perform reliably under diverse clinical conditions. The approval process can span several years, creating barriers for new products and slowing the introduction of innovative technologies. Compliance with regulatory expectations is critical for patient safety, but it also demands significant investment in clinical trials, documentation, and quality management systems, which can challenge smaller and mid-size companies attempting to enter the market.

Post-market surveillance is continuing to shape how manufacturers maintain regulatory compliance and device safety after approval. Companies are implementing systems to monitor device performance, track adverse events, and report findings to regulatory authorities. Variations in regulatory requirements across different regions are influencing global commercialization strategies, requiring manufacturers to adapt their clinical and operational approaches to multiple jurisdictions. Regulatory landscapes evolve, device developers are anticipating stricter safety standards and increased scrutiny, prompting ongoing investments in compliance infrastructure.

Presence of Alternative Pulmonary Vasodilator Therapies

Competitive pressure from other pulmonary vasodilators that are increasingly being used in managing pulmonary arterial hypertension (PAH). Therapies such as intravenous or inhaled prostacyclins, including epoprostenol and iloprost, are providing alternative pathways for reducing pulmonary vascular resistance. Phosphodiesterase-5 inhibitors such as sildenafil and endothelin receptor antagonists are also expanding treatment options for patients. Oral and less invasive formulations are gaining preference in chronic PAH management because they offer convenience, allow outpatient care, and reduce reliance on continuous hospital administration.

These alternatives are encouraging clinicians to weigh efficacy alongside patient comfort and logistics, gradually influencing treatment patterns in favor of more practical options for long-term care. The introduction of biosimilar versions of established PAH drugs is further intensifying competition by lowering treatment costs and increasing market accessibility. As more affordable alternatives become available, prescribing patterns may shift, particularly for chronic conditions where frequent hospital visits or specialized equipment pose challenges. Pharmaceutical companies are responding by developing combination therapies, novel delivery systems, and patient support programs to maintain iNO adoption in specialized neonatal and acute care settings.

Emergency and Transport Applications for iNO

The emergence of portable inhaled nitric oxide (iNO) delivery systems designed for neonatal transport and emergency medicine is creating a high-growth commercial opportunity. These devices are allowing therapy to continue seamlessly during inter-facility patient transfers, which is critical for infants experiencing respiratory distress or pulmonary hypertension. By maintaining treatment during transport, clinicians are reducing the risk of hypoxic injury and supporting better short-term and long-term outcomes. Portability and battery operation are enabling care teams to administer therapy outside traditional intensive care unit (ICU) environments, including community hospitals and emergency transport vehicles.

Companies developing transport-capable iNO platforms are positioned to establish leadership in this emerging sub-segment, as competition remains limited and clinical need is growing. Innovations in miniaturized sensors, automated flow control, and safety monitoring are enhancing device reliability during movement and ensuring consistent therapeutic delivery. Hospitals and neonatal transport programs are increasingly integrating these devices into clinical workflows to improve outcomes for critically ill infants. Portable iNO delivery systems are expected to redefine standards of care in neonatal transport and emergency medicine, driving adoption in both developed and emerging healthcare markets and reinforcing the value of continuous, point-of-care respiratory support.

Strategic Partnerships and Hospital Network Integration

Integrated procurement strategies and long-term device supply agreements are shaping a new growth pathway for inhaled nitric oxide (iNO) delivery system manufacturers. In late 2023, Vero Biotech partnered with US Med-Equip to provide on-demand access to the GENOSYL DS (a tankless iNO system). This allows hospitals to scale their capacity instantly without long-term capital investment in gas storage. Large hospital networks are increasingly centralizing purchasing decisions, allowing manufacturers to secure multi-facility contracts that provide predictable revenue streams. These agreements are facilitating streamlined device deployment across multiple sites, reducing administrative complexity and improving supply chain efficiency.

The shift toward value-based care is reinforcing the commercial relevance of iNO, as its use is linked to shorter ventilator dependency and reduced intensive care unit (ICU) length of stay. Manufacturers are increasingly collaborating with payer organizations to develop outcomes-based contracting models, where reimbursement is tied to measurable clinical benefits. These strategies are promoting the adoption of iNO as a cost-effective, clinically validated therapy across diverse hospital networks. Integrated procurement, performance-driven agreements, and strong hospital relationships will continuously shape market leadership, supporting predictable revenue growth while expanding patient access to life-saving respiratory therapies.

Application Insights

Neonatal respiratory treatment currently dominates the segment, commanding approximately 55% of total market revenue. Premature infants and newborns with conditions such as neonatal respiratory distress syndrome (nRDS) and persistent pulmonary hypertension of the newborn (PPHN) require advanced respiratory support. iNO therapy is a standard of care in these scenarios, offering targeted pulmonary vasodilation and improved oxygenation. Hospitals and neonatal intensive care units are heavily investing in devices and training to ensure safe, continuous administration.

Acute respiratory distress syndrome is likely to be the fastest-growing segment during the forecast period, driven by increasing awareness of its benefits in improving oxygenation in critically ill patients. Adult and pediatric ICUs are adopting iNO as an adjunctive therapy to conventional ventilator support, particularly in cases of severe hypoxemia. Technological advances in portable and precise iNO delivery systems are enabling more flexible and timely therapy, expanding use beyond specialized centers.

End-user Insights

Hospitals represent the dominant application segment, capturing approximately 70% of market revenue share in 2026, due to their advanced neonatal and critical care capabilities. Neonatal intensive care units and adult intensive care units (ICUs) are routinely equipped with iNO therapy for managing conditions such as neonatal respiratory distress syndrome, persistent pulmonary hypertension of the newborn (PPHN), and acute respiratory distress syndrome. Hospitals have the infrastructure, trained staff, and continuous monitoring systems required for safe iNO administration.

Specialty clinics are expected to be the fastest-growing segment over the 2026-2033 forecast period. These clinics, focusing on pulmonary care and chronic respiratory conditions, are increasingly incorporating portable and user-friendly iNO delivery systems. They offer targeted treatment for patients with pulmonary arterial hypertension (PAH), chronic obstructive pulmonary disease (COPD), and other respiratory complications. Growth is driven by the adoption of outpatient care models, shorter hospital stays, and increasing awareness of iNO’s benefits in non-acute settings. Specialty clinics are expanding therapy access, providing flexible, patient-centered solutions, and contributing to rapid market adoption beyond traditional hospital environments.

North America Inhaled Nitric Oxide (iNO) Delivery System Market Trends

North America is set to command a significant portion of the inhaled nitric oxide delivery System market share at approximately 45% in 2026, driven by strong healthcare infrastructure and sustained government investment in medical services. Hospitals and neonatal intensive care units (NICUs) are expanding capacity to support critically ill patients, including newborns with respiratory distress and adults with acute respiratory complications. Continuous advancements in healthcare technology and the pharmaceutical sector are improving the safety, efficiency, and accessibility of iNO therapy. Next-generation delivery systems with portable and precise monitoring capabilities are being integrated into hospital workflows, enabling clinicians to provide timely and effective treatment across diverse care settings.

The prevalence of respiratory diseases in the region is rising due to factors such as environmental pollution, genetic predisposition, and lifestyle changes, including higher smoking rates. This trend is increasing demand for effective respiratory treatments and driving hospitals to adopt advanced therapeutic solutions. Portable iNO devices and updated hospital protocols are allowing for continuous treatment during patient transport and emergency care. North America will continue expanding its market, with technology innovation, infrastructure growth, and a growing need for respiratory care collectively shaping adoption and strengthening the region’s leadership in this sector.

Europe Inhaled Nitric Oxide (iNO) Delivery System Market Trends

Europe is witnessing steady growth in the inhaled nitric oxide (iNO) delivery systems market, supported by a robust healthcare infrastructure and increasing prevalence of respiratory diseases such as chronic obstructive pulmonary disease (COPD) and neonatal respiratory distress syndrome (nRDS). Hospitals and neonatal intensive care units (NICUs) are adopting advanced respiratory therapies to improve patient outcomes and reduce complications associated with hypoxemia. Regulatory frameworks, including the CE Mark, are ensuring that iNO delivery systems meet high safety and quality standards, giving healthcare providers confidence in integrating these devices into clinical protocols. The emphasis on clinical excellence and adherence to standardized care practices is driving consistent adoption of iNO therapy across both public and private healthcare facilities.

Investment in medical research and healthcare innovation is further strengthening Europe’s market position. Governments and private organizations are funding clinical trials, supporting the development of next-generation iNO delivery platforms, and facilitating training programs for healthcare professionals. Hospitals are increasingly incorporating portable and user-friendly devices, which enable therapy beyond traditional intensive care units and improve access during patient transport. Europe will continue expanding its iNO market as regulatory support, research initiatives, and technological advancements converge to enhance treatment accessibility and improve outcomes for both neonatal and adult patients with respiratory complications.

Asia Pacific Inhaled Nitric Oxide (iNO) Delivery System Market Trends

Asia Pacific is anticipated to emerge as the fastest-growing inhaled nitric oxide delivery system market. Hospitals and NICUs in the region are integrating advanced therapies to address the growing clinical need, ensuring timely intervention for critically ill patients. The adoption of iNO therapy is expanding as clinicians recognize its ability to improve oxygenation, reduce ventilator dependency, and enhance patient outcomes. Regional healthcare systems are upgrading infrastructure to accommodate specialized respiratory treatments, including portable and next-generation iNO delivery platforms that enable therapy beyond traditional intensive care settings.

Government initiatives and private investment in healthcare development are supporting market expansion across countries such as India, China, and Japan. Funding is focused on modernizing hospitals, training medical personnel, and procuring advanced respiratory care devices, which are increasing therapy accessibility for both neonates and adults. The Asia Pacific is expected to witness accelerated adoption of iNO systems as healthcare networks expand, clinical guidelines evolve, and portable, cost-effective devices become widely available. This combination of rising disease prevalence and infrastructure enhancement is positioning the region as one of the fastest-growing markets for iNO delivery solutions.

The global inhaled nitric oxide (iNO) delivery system market structure is moderately consolidated, dominated by leading players such as Mallinckrodt Pharmaceuticals, Linde plc, Air Liquide Healthcare, and Vero Biotech. These players collectively capture 35-40% of the market share. The market is witnessing the rise of emerging players introducing innovative, portable delivery platforms aimed at hospital transport and expanding access in emerging markets. These new entrants are focusing on compact, user-friendly devices that enable therapy during patient transfers and in settings with limited infrastructure. Despite these opportunities, barriers to entry remain significant. Companies must navigate rigorous regulatory approval processes, generate strong clinical evidence to demonstrate safety and efficacy, and ensure reliable gas supply infrastructure. Overcoming these challenges is essential for new players to establish a foothold and compete effectively in the iNO market.

Key Developments:

• In June 2025, Beyond Air submitted a PMA supplement to the FDA for LungFit PH II, its next-generation nitric oxide generator for treating persistent pulmonary hypertension of the newborn (PPHN). The upgraded system is smaller, lighter, and fully transportable while retaining core features like patented Ionizer technology for on-demand NO generation from ambient air (0.5-80 ppm doses) and the same Smart Filters for NO2 removal, ensuring seamless compatibility for hospital users.